Analytical Data
-
Gene name
KIAA0247
- Application
-
Alternative Names
SUSD6; DRAGO; KIAA0247; Sushi domain-containing protein 6; Drug-activated gene overexpressed protein
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92537
-
Expression Region
1-303aa
-
AA Sequence
MCHGRIAPKSTSVFAVASVGHGVFLPLVILCTLLGDGLASVCPLPPEPENGGYICHPRPCRDPLTAGSVIEYLCAEGYMLKGDYKYLTCKNGEWKPAMEISCRLNEDKDTHTSLGVPTLSIVASTASSVALILLLVVLFVLLQPKLKSFHHSRRDQGVSGDQVSIMVDGVQVALPSYEEAVYGSSGHCVPPADPRVQIVLSEGSGPSGRSVPREQQLPDQGACSSAGGEDEAPGQSGLCEAWGSRASETVMVHQATTSSWVAGSGNRQLAHKETADSENSDIQSLLSLTSEEYTDDIPLLKEA
-
Molecular Weight
58.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIAA0247, also known as a candidate cancer-associated gene, has garnered attention in recent years due to its potential roles in various biological processes and diseases, particularly cancer. Initially identified through large-scale genomic and transcriptomic analyses, KIAA0247 is located on chromosome 18 and is thought to be involved in cell signaling, proliferation, and possibly tumorigenesis. Its expression levels have been correlated with several malignancies, indicating a potential role in cancer progression and metastasis. Research suggests that KIAA0247 might interact with key signaling pathways and cellular mechanisms, offering insights into tumor biology and potential therapeutic targets. Additionally, the recombinant protein of KIAA0247 provides a valuable tool for studying its functional roles and interactions in vitro and in vivo. Understanding the molecular mechanisms mediated by KIAA0247 could unveil new approaches for cancer diagnosis and treatment, making it a focal point in current cancer research. As such, further investigation into the structure, function, and clinical relevance of KIAA0247 is imperative to elucidate its contributions to oncogenesis and to explore its potential as a biomarker or therapeutic target in oncology.
